Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some safety/side-effect claims (drowsiness/dizziness/lightheadedness; nausea/vomiting; blurred vision) are supported by the label’s Adverse Reactions and/or Information for Patients. However, multiple mechanistic/pharmacologic assertions (specific CNS pathway effects and brain/spinal cord localization) are not established in the label, and the AI’s indication framing omits that the exact mechanism is not clearly identified and includes “short-term” which is not stated as such in the provided label text.
Category Scores
Accurate Statements
Methocarbamol commonly causes drowsiness.
Adverse Reactions: 'drowsiness' and 'sedation' under Nervous system; Information for Patients: 'may cause drowsiness'.
Methocarbamol commonly causes dizziness.
Adverse Reactions: 'dizziness or lightheadedness' under Nervous system.
Methocarbamol commonly causes lightheadedness.
Adverse Reactions: 'dizziness or lightheadedness' under Nervous system.
Other potential side effects of methocarbamol include nausea.
Adverse Reactions: 'Nausea and vomiting' under Digestive system; Overdosage symptoms include 'nausea'.
Other potential side effects of methocarbamol include vomiting.
Adverse Reactions: 'Nausea and vomiting' under Digestive system; Overdosage symptoms include 'nausea' (vomiting also listed in adverse reactions).
Other potential side effects of methocarbamol include blurred vision.
Adverse Reactions: 'Blurred vision' under Skin and special senses.
Methocarbamol is often used in conjunction with rest and physical therapy.
Indications and Usage: 'adjunct to rest, physical therapy, and other measures'.
Unsupported Statements
Methocarbamol is classified as a muscle relaxant.
The provided label excerpts do not use the term 'muscle relaxant' or provide a classification statement.
Methocarbamol works by acting on the central nervous system to relieve muscle spasms and pain.
Label states the mechanism has not been established and 'may be due to general CNS depression', but it does not state a mechanism that relieves 'muscle spasms and pain' specifically. Indication text does not claim an established mechanism beyond 'may be related to its sedative properties'.
Methocarbamol acts centrally, likely in the brain and spinal cord, to depress overall central nervous system activity.
The label says mechanism is 'may be related to' general CNS depression, but does not localize to 'brain and spinal cord' or say 'likely' in that manner.
Suppression of overall central nervous system activity from methocarbamol is thought to interfere with nerve pathways that transmit pain signals from injured muscles to the brain, thereby reducing spasm and discomfort.
The label says mechanism is not established and may involve general CNS depression; it does not describe interfering with nerve pathways transmitting pain signals to the brain.
Methocarbamol is typically prescribed for short-term relief of discomfort associated with acute, painful musculoskeletal conditions.
While the indication specifies acute painful musculoskeletal conditions and is 'adjunct to rest, physical therapy, and other measures', the provided label text does not state 'typically prescribed for short-term relief'.
Contradictions
Low
AI Statement
Methocarbamol works by acting on the central nervous system to relieve muscle spasms and pain.
Label Reference
INDICATIONS AND USAGE: 'Methocarbamol does not directly relax tense skeletal muscles in man.'
Important Omissions
Contraindication details are not addressed in the AI claims provided (e.g., hypersensitivity to methocarbamol/tablet components).
Importance:
Moderate
Caution about impaired hazardous-task performance (operating machinery/driving) is not explicitly tied to the AI’s side-effect/drowsiness claims in the provided claim set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Mechanism/localization claims that are not supported could mislead regarding how the drug works; however, multiple safety-related adverse-effect statements (drowsiness/dizziness/lightheadedness; nausea/vomiting; blurred vision) are label-supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Mechanistic assertions (brain/spinal cord localization; nerve pathway interference for pain/spasm) are not established in the label excerpts and go beyond labeled statements about general CNS depression/sedative properties and lack of established MOA.
Suggested Improvement
Restrict mechanism language to what the label states: MOA not clearly identified; may be related to sedative properties/general CNS depression; and include that methocarbamol does not directly relax tense skeletal muscles in man. Avoid adding specific pain-nerve-pathway or brain/spinal-cord localization details not present in the provided label text.